Efficacy of a high potency O 1 Manisa foot-and-mouth disease vaccine in cattle against heterologous challenge with a field virus from the O/ME-SA/Ind-2001 lineage collected in North Africa

Fishbourne, Emma; Ludi, Anna B.; Wilsden, Ginette; Hamblin, Pip; Statham, Bob; Bin-Tarif, A.; Brocchi, Emiliana; Grazioli, Santina; Dekker, A.; Eblé, P.L.; King, Donald P.

doi:10.1016/j.vaccine.2017.02.047

Cited by 28 publications

(28 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, managers of vaccine banks should not require vaccine of >6 PD 50 /dose but should know the homologous potency to be able to predict the protection against circulating field viruses, using in-vitro vaccine matching results (e.g., r 1 -value) as predictor of the cross-protection-ratio. Although in this study and a previous study [22] the cross-protection-ratio matches reasonably well with the r 1 -value, more research is needed to validate this for more strains, especially as the variation in both r 1 -value determination and potency tests is considerable [23][24][25][26].…”

Section: Discussionsupporting

confidence: 70%

“…The formula above shows that under the assumption that one should have at least 3 PD 50 /dose against the heterologous field virus; the cross-protection-ratio (and probably the r 1 -value) should not be below 0.5. However, the homologous potency of emergency vaccines is often much larger than 6 PD 50 /dose [6][7][8][9]22]. Therefore, managers of vaccine banks should not require vaccine of >6 PD 50 /dose but should know the homologous potency to be able to predict the protection against circulating field viruses, using in-vitro vaccine matching results (e.g., r 1 -value) as predictor of the cross-protection-ratio.…”

Section: Discussionmentioning

confidence: 99%

“…The raw data are available online at http://www.mdpi.com/2076-393X/8/1/24/s1: Supplementary Table S1a. VNT titres against A 22 /IRQ/64 vaccine strain in vaccinated and unvaccinated cattle in the full dose protection test. Supplementary Table S1b.…”

Section: Supplementary Materialsmentioning

confidence: 99%

See 2 more Smart Citations

Cross-Protection Induced by a A/MAY/97 Emergency Vaccine Against Intra-Serotype Heterologous Challenge with a Foot-and-Mouth Disease Virus from the A/ASIA/G-VII Lineage

et al. 2020

Self Cite

View full text Add to dashboard Cite

Since 2015, outbreaks of foot-and-mouth disease (FMD) in the Middle East have been caused by a new emerging viral lineage, A/ASIA/G-VII. Invitro vaccine matching data indicated that this virus poorly matched (low r 1 -value) with vaccines that were being used in the region as well as most other commercially available vaccines. The aim of this study was to assess the performance of two candidate vaccines against challenge with a representative field virus from the A/ASIA/G-VII lineage. The results from an initial full dose protection study provided encouraging data for the A/MAY/97 vaccine, while the A 22 /IRQ/64 vaccine only protected 2/7 vaccinated animals. In view of these promising results, this vaccine was tested in a potency test (PD 50 ) experiment in which 5 cattle were vaccinated with a full dose, 5 cattle with a 1/3 dose and 5 cattle with a 1/9 dose of vaccine. At 21 days post vaccination these vaccinated cattle and 3 control cattle were challenged intradermolingually with a field isolate from the A/ASIA/G-VII lineage. The intra-serotype heterologous potency test resulted in an intra-serotype heterologous potency of 6.5 PD 50 /dose. These data support previous studies showing that a high potency emergency vaccine can protect against clinical disease when challenged with a heterologous strain of the same serotype, indicating that not only the r 1 -value of the vaccine, but also the homologous potency of a vaccine should be taken into account when advising vaccines to control an outbreak.

show abstract

Section: Discussionsupporting

confidence: 70%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cross-Protection Induced by a A/MAY/97 Emergency Vaccine Against Intra-Serotype Heterologous Challenge with a Foot-and-Mouth Disease Virus from the A/ASIA/G-VII Lineage

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…r1-value) as predictor of the cross-protection-ratio. Although in this study and a previous study [22] the cross-protection-ratio matches reasonably well with the r1-value, more research is needed to validate this for more strains, especially as the variation in both r1-value determination and potency tests is considerable [23][24][25][26].…”

Section: Cross-protection-ratio =supporting

confidence: 67%

“…The formula above shows that under the assumption that one should have at least 3 PD50/dose against the heterologous field virus; the cross-protectionratio (and probably the r1-value) should not be below 0.5. However, the homologous potency of emergency vaccines is often much larger than 6 PD50/dose [6][7][8][9]22]. Therefore, managers of vaccine banks should not require vaccine of >6 PD50/dose but should know the homologous potency to be able to predict the protection against circulating field viruses, using in-vitro vaccine matching results (e.g.…”

Section: Cross-protection-ratio =mentioning

confidence: 99%

Cross-protection induced by a A/MAY/97 Emergency Vaccine Against Heterologous Challenge with a Foot-and-mouth Disease Virus from the A/ASIA/G-VII Lineage

Dekker¹,

Sanz-Bernardo²,

Singanallur³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Since 2015, outbreaks of foot-and-mouth disease (FMD) in the Middle East have been caused by a new emerging viral lineage, A/ASIA/G-VII. In-vitro vaccine matching data indicated that this virus poorly matched (low r1-value) with vaccines that were being used in the region as well as most other commercially available vaccines. The aim of this study was to assess the performance of two candidate vaccines against challenge with a representative field virus from the A/ASIA/G-VII lineage. The results from an initial full dose protection study provided encouraging data for the A/MAY/97 vaccine, while the A22/IRQ/64 vaccine only protected 2/7 vaccinated animals. In view of these promising results, this vaccine was tested in a potency test (PD50) experiment in which 5 cattle were vaccinated with a full dose, 5 cattle with a 1/3 dose and 5 cattle with a 1/9 dose of vaccine. Vaccines were prepared as would be done during an emergency vaccination campaign using a double oil emulsion adjuvant. At 21 days post vaccination these vaccinated cattle and 3 control cattle were subsequently challenged intradermolingually with a field isolate from the A/ASIA/G-VII lineage. All cattle from the full vaccine dose, 4 cattle from the 1/3 vaccine dose and 2 cattle from the 1/9 vaccine dose were clinically protected against challenge with FMDV A/ASIA/G-VII, resulting in a heterologous potency of 6.5 PD50/dose. These data support previous studies showing that a high potency emergency vaccine can protect against clinical disease when challenged with a heterologous strain of the same serotype. Not only the r1-value of the vaccine, but also the homologous potency of a vaccine should be taken into account when advising vaccines to control an outbreak.

show abstract

Photobiomodulation therapy for the prevention of acute radiation dermatitis in breast cancer patients undergoing hypofractioned whole‐breast irradiation (LABRA trial)

et al. 2021

View full text Add to dashboard Cite

Objectives: To evaluate the efficacy of photobiomodulation therapy in breast cancer patients post-lumpectomy undergoing hypofractionated whole-breast irradiation (HF-WBI) for the prevention and management of acute radiodermatitis (ARD). Materials and Methods: A randomized, multicentric clinical trial (LABRA trial, NCT03924011) was set up at the Limburg Oncology Center, including the Jessa Hospital (Hasselt, BE) and Ziekenhuis Oost-Limburg (Genk, BE). A total of 71 breast cancer patients planned to undergo HF-WBI were randomized to one of the two study arms: the control group (n = 32) or the PBM group (n = 39). The PBM group received the standard institutional skincare combined with PBM (2×/week) during the complete radiotherapy (RT) course. Patients in the control group received the standard skincare combined with placebo treatment (2x/week). Patients' skin reactions were evaluated weekly during the RT treatment by using the modified version of the Radiation Therapy Oncology Group (RTOG) criteria. Results: At week 3 of RT, one patient presented a grade 2 and one patient a grade 3 skin reaction in the control group, while in the PBM group, all patients still presented grade 1 ARD. At the final RT session 28% of the patients presenting grade 2-3 ARD, while in the PBM group 10% presented grade 2 and no grade 3 ARD. PBM reduced the incidence of severe ARD by 18%. However, the difference was not significant (p = 0.053). Conclusion: Based on the LABRA trial results, PBM seems not able to reduce the incidence of severe ARD in breast cancer patients undergoing HF-WBI. Research in a larger patient population is recommended.

show abstract

Efficacy of a high potency O 1 Manisa foot-and-mouth disease vaccine in cattle against heterologous challenge with a field virus from the O/ME-SA/Ind-2001 lineage collected in North Africa

Cited by 28 publications

References 14 publications

Cross-Protection Induced by a A/MAY/97 Emergency Vaccine Against Intra-Serotype Heterologous Challenge with a Foot-and-Mouth Disease Virus from the A/ASIA/G-VII Lineage

Cross-Protection Induced by a A/MAY/97 Emergency Vaccine Against Intra-Serotype Heterologous Challenge with a Foot-and-Mouth Disease Virus from the A/ASIA/G-VII Lineage

Cross-protection induced by a A/MAY/97 Emergency Vaccine Against Heterologous Challenge with a Foot-and-mouth Disease Virus from the A/ASIA/G-VII Lineage

Photobiomodulation therapy for the prevention of acute radiation dermatitis in breast cancer patients undergoing hypofractioned whole‐breast irradiation (LABRA trial)

Contact Info

Product

Resources

About